The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
Conceptualized as an aggregator platform it integrates existing programme systems through an API-based federated architecture
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence
The private funding rose 38% amid growing international collaborations and CDMO demand
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Leadership transition strengthens Redcliffe Labs’ focus on scaling technology-led diagnostics, operational excellence, and preventive healthcare access
Subscribe To Our Newsletter & Stay Updated
